Mechanism of action<unk>  inhibits growth of tumour cells by blocking subunit alpha of the platelet-derived growth factor receptor, a type of tyrosine kinase. Pharmacokinetics After intravenous infusion,<unk>  has a volume of distribution of 7.7 litres in steady state and a biological half-life of 11 days.
Olaratumab
Ustekinumab
Emapalumab
Evolocumab
Evinacumab
Dupilumab
Anifrolumab
Alirocumab